


# Personalized Health Series

The death of data sharing?

A modern privacy technology survival kit

15.05.2025



University  
of Basel



Universitätsspital  
Basel



# Data Sharing

VII Joint Workshop

## University of Basel, University Hospital of Basel, Roche

**Date:** 15 May 2025

**Venue:** Roche, Grenzacherstrasse 124, Basel, Building 1, Auditorium 2nd Floor

Registration in the lobby

**Time:** 13:00 - 18:00

**Background:** On the 16th of September 2021, the first workshop of the Personalized Health Series, jointly organised by the University of Basel, the University Hospital of Basel and Interpharma, took virtually place in Basel. That very first meeting was focused on Digital Biomarkers. With the overarching topic of personalized medicine in mind, many other workshops have been held, focused on drug repurposing, federated learning and MedTech.

The goal of this series is to foster and strengthen partnerships and collaborations between industry and university, and define a few pilot projects, leading to innovation and societal impact. That goal still holds as the most important objective of the whole series of events.

**Present:** Exchanging raw sensitive health-data across hospitals, data providers and different countries raises huge questions concerning privacy. Nevertheless, fostering collaborations among public institutions, and between academia and private industries is urgent and of paramount importance for the potential achievements and benefits for the patients. In order to facilitate the exchange of sensitive health-data, while preserving privacy, innovative strategies are being implemented. The workshop will explore some of them, such as federated learning and synthetic data, among others. PHB and Roche are joining forces to bring you a new exciting event. Interventions from academia and industry will not only present the current situation, but will try to outline possible solutions from both a technical and a legal point of view, by discussing the latest results and real use cases, in the framework of academia-industry partnerships. The event wants to offer the chance to showcase running projects, and be a catalyst for collaborations in such a realm.

# Program

12:30 **Doors open**

13:00 - 13:15 **Welcome**

*Cristina Golfieri, Manager of Personalized Health Basel*

*Katrin Madjar, Senior Statistical Scientist, Roche*

## **Risks, legal aspects and survival**

13:15 - 13:30 Global Data Sharing at Risk - A Legal Perspective

*Tobias Schulte in den Bäumen, Roche*

13:30 - 14:00 New data protection and privacy laws - Is scientific innovation at risk?

*Debate with Alfred Früh, University of Basel, and Tobias Schulte in den Bäumen, Roche*

14:00 - 14:15 A survival kit

*Peter Krusche, Novartis*

14:15 - 14:45 **1. Keynote**

Privacy-Preserving Federated Learning with Strong Guarantees for Clinical Dermatology

*Philippe Gottfrois, University Hospital Basel*

14:45 - 15:05 **1. Pitching session**

a. Mechanistic simulations as an enabling technology for AI: Synergies between physics-based and data-driven models in medical research

*Axel Loewe, KIT, Germany*

b. Transforming scientific discovery with collaborative federated ecosystems

*Frederik Buijs & Joël Federer-Gsponer, Roche*

c. Federated Learning For Diagnostics of Rare Diseases with Immunoprofiling,

*Enkelejda Miho, FHNW*

d. Innovative paths to privacy- and sovereignty-compliant data usage in Post-COVID research and beyond

*Irina Tihaa, d-fine*

15:05 - 15:30 **Coffee Break**

# Program

15:30 - 16:00 **2. Keynote**

Collaboration without compromise: New models of data partnerships between Pharma and Healthcare providers

*Astrid Kiermaier (Roche), Bram Stieltjes (USB), Armin Scheuer (MDClone)*

16:00 - 16:20 **2. Pitching session**

- a. Data sharing for rare diseases in the European consortium INVENTS - the Roche perspective  
*Markus Elze, Roche*
- b. How to collect and share medical data without compromising patient's anonymity: a prostate cancer screening use case  
*Nicolas Martelin, Prostperia*
- c. The death of modern privacy technology survival kits? A mature data anonymization survival kit  
*Matthias Templ, FHNW*
- d. Privacy-Preserving Use of Medical Audio Data  
*Julian Kempf, Anamedia*

16:20 - 17:00 **Panel discussion - Use of the survival kit to share data and collaborate. How to remove obstacles and foster partnerships?**

**Panelists:** Astrid Kiermaier, Roche  
Peter Krusche, Novartis  
Alfred Früh, University of Basel  
Bram Stieltjes, University Hospital Basel

**Moderator:** Dominik Heinzmann, Roche

17:00 - 18:15 **Apéro**

**PERSONALIZED  
HEALTH  
BASEL**



Personalized Health Basel (PHB) is a joint effort of the University of Basel, the University Hospital Basel and the Children Hospital Basel. Its goal is to support local research groups working on personalized medicine and promote translational research. Furthermore, PHB aims to build bridges between academic researchers and private companies to foster collaborations and partnerships and launch pilot-projects in the field of data ecosystem and personalized health.



Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. Roche is a pioneer in personalised healthcare and want to further

transform how healthcare is delivered to have an even greater impact. To provide the best care for each person Roche partners with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, Roche's greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit [www.roche.com](http://www.roche.com)

**Organizers' contacts:**

Raffaello Ferone (Personalized Health Basel) - [raffaello.ferone@unibas.ch](mailto:raffaello.ferone@unibas.ch)

Katrin Madjar (Roche) - [katrin.madjar@roche.com](mailto:katrin.madjar@roche.com)